文献速递结核与非结核分枝杆菌

结核病:新诊断方法与生物标志物研发的进展与挑战

Tuberculosis: advances and challenges in development of new diagnostics and biomarkers.
PubMed 文献 · Lancet Infect Dis · 2018-03-23

本文综述结核病新诊断方法与生物标志物的研发进展。肺外结核及儿童、HIV感染者、孕妇结核诊断尤为困难,急需更准确、快速、经济的筛查检测及能指示潜伏感染进展、预测复发风险和作为药物疫苗试验终点的生物标志物。

要点

  • 肺外结核及儿童、HIV感染者、孕妇结核诊断尤为困难
  • 急需能指示潜伏感染进展、预测复发风险及作为试验终点的生物标志物

核心结论

  • 结核病仍是全球感染性疾病死亡的首位原因,早期准确诊断药物敏感和耐药结核对实现全球结核控制至关重要。
  • 生物标志物急需用于指示潜伏感染进展为临床疾病、预测治愈后复发风险以及为药物和疫苗试验提供准确终点。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • 肺外结核及儿童、HIV感染者、孕妇的结核诊断仍尤为困难。
  • 诊断分子技术领域持续扩展,包括针对多种抗结核药物耐药性的检测开发。
  • 复杂生物信息学计算工具和系统生物学方法正应用于生物标志物的发现和验证,并已取得实质性进展。
  • 新数据来自T细胞反应和T细胞功能研究、血清学研究、流式细胞术检测以及蛋白和基因表达研究。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步投资,包括影响评估和成本效益研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis remains the leading cause of death from an infectious disease worldwide. Early and accurate diagnosis and detection of drug-sensitive and drug-resistant tuberculosis is essential for achieving global tuberculosis control. Despite the introduction of the Xpert MTB/RIF assay as the first-line rapid tuberculosis diagnostic test, the gap between global estimates of incidence and new case notifications is 4·1 million people. More accurate, rapid, and cost-effective screening tests are needed to improve case detection. Diagnosis of extrapulmonary tuberculosis and tuberculosis in children, people living with HIV, and pregnant women remains particularly problematic. The diagnostic molecular technology landscape has continued to expand, including the development of tests for resistance to several antituberculosis drugs. Biomarkers are urgently needed to indicate progression from latent infection to clinical disease, to predict risk of reactivation after cure, and to provide accurate endpoints for drug and vaccine trials. Sophisticated bioinformatic computational tools and systems biology approaches are being applied to the discovery and validation of biomarkers, with substantial progress taking place. New data have been generated from the study of T-cell responses and T-cell function, serological studies, flow cytometric-based assays, and protein and gene expression studies. Alternative diagnostic strategies under investigation as potential screening and triaging tools include non-sputum-based detection with breath-based tests and automated digital radiography. We review developments and key achievements in the search for new tuberculosis diagnostics and biomarkers. We highlight gaps and challenges in evaluation and rollout of new diagnostics and biomarkers, and prioritise areas needing further investment, including impact assessment and cost-benefit studies.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Walzl G, McNerney R, du Plessis N, et al. Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infect Dis. 2018. PMID: 29580818. doi:10.1016/S1473-3099(18)30111-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。